What Proportion of Patients With Inflammatory Bowel Disease Want to Stop Infliximab Therapy?
*Inserm, U954 and Department of Hepato-Gastroenterology, Nancy University Hospital, Lorraine University, France †ESPRI-BioBase Unit, Platform of Clinical Research Support PARC, Nancy University Hospital, Lorraine University, France ‡Division of Gastroenterology, Ulster Hospital, Belfast, Ireland.
Guillaume
G
Conroy
Isabelle
I
Clerc-Urmès
Patrick B
PB
Allen
Cedric
C
Baumann
Laurent
L
Peyrin-Biroulet
D000328:Adult; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy*; D000069285:Infliximab / Q000627:therapeutic use*; D008297:Male; D057240:Patient Preference / Q000523:psychology / Q000706:statistics & numerical data*; D011788:Quality of Life; D011795:Surveys and Questionnaires
D005765:Gastrointestinal Agents; D000069285:Infliximab